Liqing Hu Selected Research

aminoglycoside N(3')-acetyltransferase

1/2022

Whole genome sequence of EC16, a blaNDM-5-, blaCTX-M-55-, and fosA3-coproducing Escherichia coli ST167 clinical isolate from China.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Liqing Hu Research Topics

Disease

4	Pulmonary Arterial Hypertension 01/2022 - 01/2019
3	Vascular Remodeling 01/2022 - 10/2020
2	Hypoxia (Hypoxemia) 01/2022 - 01/2021
2	Pulmonary Hypertension 01/2022 - 01/2021
1	Congenital Abnormalities (Deformity) 01/2022
1	Spontaneous Abortion (Miscarriage) 01/2022
1	Aneuploidy (Aneuploid) 01/2022
1	Fibrosis (Cirrhosis) 01/2022
1	Infections 01/2022
1	Inflammation (Inflammations) 01/2022
1	Melanoma (Melanoma, Malignant) 01/2020
1	alpha-Thalassemia 09/2014
1	Thalassemia 09/2014
1	Tuberculosis (Tuberculoses) 06/2013

Drug/Important Bio-Agent (IBA)

3	Pharmaceutical PreparationsIBA 10/2020 - 06/2013
2	riociguatIBA 01/2021 - 01/2019
2	benzocycloheptapyridineIBA 01/2021 - 10/2020
1	dichlorobis(azomycin)platinum IIIBA 01/2022
1	aminoglycoside N(3')-acetyltransferaseIBA 01/2022
1	Sildenafil Citrate (Viagra)FDA Link 01/2022
1	Cell-Free Nucleic AcidsIBA 01/2022
1	Protein Kinases (Protein Kinase)IBA 01/2022
1	Biomarkers (Surrogate Marker)IBA 01/2022
1	MonocrotalineIBA 01/2022
1	Platelet-Derived Growth FactorIBA 01/2021
1	AMP-Activated Protein KinasesIBA 10/2020
1	Soluble Guanylyl CyclaseIBA 10/2020
1	Cardiovascular AgentsIBA 01/2020
1	Propranolol (Inderal)FDA LinkGeneric 01/2020
1	Adrenergic Receptors (Adrenergic Receptor)IBA 01/2020
1	Heat-Shock Proteins (Heat-Shock Protein)IBA 01/2020
1	Biological ProductsIBA 01/2020
1	hemoglobin Q ThailandIBA 09/2014

Therapy/Procedure

3	Therapeutics 01/2022 - 01/2020
1	Oral Administration 01/2022
1	Secondary Prevention 01/2022